THE HEPATITIS C VIRUS PROTEASE INHIBITOR TELAPREVIR IN THERAPY REGIMENS FOR CHRONIC HEPATITIS C IN PATIENTS WITH HIV INFECTION
- Authors: KRAVCHENKO A.V.1, KANESTRI V.G1
-
Affiliations:
- Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
- Issue: No 2 (2013)
- Pages: 68-72
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/276610
- ID: 276610
Cite item
Open Access
Access granted
Abstract
The paper gives current recommendations for the use of the new hepatitis C virus (HCV) protease inhibitor telaprevir to treat chronic hepatitis C in HIV-infected patients who have and have not received antiviral therapy before. It also provides data of trials evaluating the efficacy and safety of telaprevir in combination with pegylated interferon and ribavirin in patients with mixed infection (HIV/HCV) and HCV genotype 1 who have not received therapy for chronic hepatitis C. Prognostic criteria for the possibility of achieving a sustained virological response to treatment are defined. Drug interactions between HCV protease inhibitors and antiretroviral drugs are described.
Keywords
Full Text
About the authors
Alexey V. KRAVCHENKO
Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
Email: kravtchenko@hivrussia.net
V. G KANESTRI
Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
Email: kanestry@yandex.ru
References
- Jacobson I.M., McHutchison J.G., Dusheiko G. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405—2416.
- Poordad F., McCone J., Bacon B.R. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195—1206.
- Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 6.1; November, 2012). European AIDS Clinical Society. http://www.europeanaidsclinicalsociety.org
- Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). February 12, 2013. http://AIDSinfo.nih.gov
- Thompson M.A., Aberg J.A., Hoy J.F. et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308(4): 387—402.
- Sulkowski M.S., Sherman K.E., Soriano V. et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV coinfected patients: SVR24 final study results. Program and abstracts of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts, 2012; аbstract 54.
- vanHeeswijkR.,VandevoordeA.,BoogaertsG.etal.Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers.18th Conference on Retroviruses and Opportunistic Infections (CROI 2011). Boston, 2011; аbstract 119.
- Кравченко А.В., Канестри В.Г., Куимова УА. Современние рекомендации по применению ингибиторов протеази виру-са гепатита С у пациентов с сочетанной инфекцией (ВИЧ-инфекция/хронический гепатит С). Инфекционние болезни 2012; 10(3): 90—95.
- Покровский В.В., Юрин О.Г., Кравченко А.В. и др. Протоколи диспансерного наблюдения и лечения больних ВИЧ-инфекцией. Национальное научное общество инфек-ционистов. Эпидемиол. инфекц. болезни. Актуал. вопр. 2012; 6, приложение. 28 с.
- Ingiliz P., Rockstroh J.K. HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver International 2012; 32(8): 1194—1199.
- Кравченко А.В., Канестри В.Г., Куимова У.А. и др. Антиретровирусная терапия пациентов с сочетанной инфекцией ВИЧ-инфекция/хронический вирусний гепатит. Медицинский алфавит. Эпидемиология и санитария 2011; 3: 16—25.
Supplementary files
